カテゴリ： GlobalData, アメリカ, 企業調査

Agilent Technologies Inc (A)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Agilent Technologies Inc (A) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013483
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Agilent Technologies Inc (Agilent) is a provider of instruments, reagents, software, services and consumables for comprehensive laboratory workflow. Its product portfolio comprises atomic absorption systems, bioanalyzers, gene expression microarrays and automation systems, among others. The company offers its products to diagnostics, life sciences and applied chemical markets. It serves biotechnology, pharmaceutical, contract research organizations (CROs) and contract manufacturing organizations (CMOs), chemical and energy, environmental and forensics, and food industries. Agilent markets its products through direct sales force, distributors, manufacturers’ representatives, resellers and e-commerce. It has research and development (R&D) and manufacturing facilities in the US, Denmark, Germany, Italy, Japan, Malaysia, China, Singapore and Australia. Agilent is headquartered in Santa Clara, California, the US.

Agilent Technologies Inc (A) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Agilent Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Agilent Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Agilent Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Agilent Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Agilent Technologies Inc, Medical Devices Deals, 2011 to YTD 2017 11
Agilent Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Agilent Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Agilent Technologies Acquires Product Line Of Aurora SFC Systems 15
Venture Financing 16
Molecular Assemblies Raises USD2.3 Million in Seed Financing 16
Partnerships 17
Agilent Tech Extends its Agreement with University of Leuven – Center for Human Genetics and University Hospitals Leuven 17
Agilent Technologies Enters into Agreement with Transcriptic 18
Agilent Technologies Enters into Distributuion Agreement with PureHoney Technologies 19
Protea Biosciences Enters into Agreement with Agilent Technologies 20
Agilent Technologies Enters into Agreement with Bioprocessing Technology Institute 21
Dako Enters into Development Agreement with ONO PHARMA for Opdivo 22
Agilent Technologies And CambTEK Enter Into Co-Marketing Agreement For Sample Prep Technologies 23
Agilent Technologies Enters Into Agreement With Cell Line Genetics For Regenerative Medicine 24
Agilent Technologies Enters Into Co-Marketing Agreement Picometrics 25
Dako Enters Into Co-Development Agreement With Merck 26
Agilent Technologies Enters Into Research Agreement With University of Queensland 27
ModiQuest Research Extends Agreement With Dako To Generate Monoclonal Antibody 28
Agilent Enters Into Research Agreement With Daegu Gyeongbuk Institute of Science And Technology 29
Agilent Technologies Enters Into Co-Development Agreement With Seoul National University Hospital 30
Agilent Technologies Enters Into Agreement With SomaLogic For SOMAscan Proteomic Assay 31
Agilent Technologies Enters Into Agreement With University of Rouen And Bioprocessing Technology Institute For Biologics And Vaccine Analysis 32
Agilent Enters Into Research Agreement With Chungnam National University 33
Agilent Technologies Enters Into Agreement With Applied Proteomics 34
Agilent Technologies Enters Into Research Agreement With Centre for Omic Sciences For Systems Biology 35
Agilent Technologies Enters Into Technology Integration Agreement With Premier Biosoft International 36
Agilent Technologies Enters Into Co-Development Agreement With Beijing Genomics Institute 37
Dako Enters Into Co-Development Agreement With Amgen 38
Dako Enters Into Co-Development Agreement With Amgen 39
Dako Enters Into Co-Development Agreement With Bristol-Myers 40
Agilent Technologies And University of Technology Sydney Expand Their Joint Venture 41
Agilent Technologies Enters Into Co-Development Agreement With Chungnam National University 42
Agilent Technologies Enters Into Research And Development Agreement With National University Of Singapore 43
Dako Denmark Enters Into Co-Development Agreement With Epitomics 44
Agilent Technologies Enters Into Co-Marketing Agreement With Sage Science 45
Nikon Instruments Enters Into Distribution Agreement With Agilent Technologies 46
Licensing Agreements 47
Dako Enters into Licensing Agreement with OriGene Technologies 47
Population Genetics Enters Into Licensing Agreement With Agilent Technologies For VeriTag Technology 48
Debt Offering 49
Agilent Technologies Completes Public Offering Of Notes Due 2022 For US$400 Million 49
Acquisition 51
Agilent Technologies Acquires 48% Stake in Lasergen for USD80 Million 51
Agilent Technologies Acquires Cartagenia for USD68.34 Million 52
Agilent Technologies To Acquire ABC Instrumentacion Analitica 53
Agilent Technologies Acquires Minority Stake In Gen9 For US$21 Million 54
Agilent Technologies Completes Acquisition Of Dako From EQT For US$2.2 Billion 55
Agilent Technologies Completes Acquisition Of BioSystem Development 57
Agilent Technologies Acquires Halo Genomics 58
Agilent Technologies Acquires BIOCIUS Life Sciences 59
Agilent Technologies Inc – Key Competitors 60
Agilent Technologies Inc – Key Employees 61
Agilent Technologies Inc – Locations And Subsidiaries 63
Head Office 63
Other Locations & Subsidiaries 63
Recent Developments 64
Strategy And Business Planning 64
Aug 09, 2016: Agilent Technologies to Build New Facility in Colorado, Increasing Pharmaceutical Manufacturing Capacity 64
Financial Announcements 65
Nov 20, 2017: Agilent Technologies Reports Fourth-Quarter Fiscal Year 2017 Financial Results 65
Aug 15, 2017: Agilent Technologies Reports Third-Quarter Fiscal Year 2017 Financial Results 66
Corporate Communications 67
Jul 18, 2017: Hans E. Bishop to Join Agilent’s Board of Directors 67
Legal and Regulatory 68
May 19, 2016: Twist Bioscience Retains Leading Law Firm Quinn Emanuel to Combat Lawsuit Filed by Agilent Technologies 68
Jan 06, 2016: ENZO Biochem Reaches $9 Million Patent Infringement Settlement with Agilent Technologies 69
Product News 70
Oct 10, 2016: Agilent Technologies showcases innovative laboratory solutions at analytica China 2016 70
Sep 13, 2016: Agilent Technologies Lowers the Cost of Multi-Element Analysis 71
Aug 30, 2016: Agilent Technologies Introduces Transformational Technology for Gas Chromatography 72
Jun 06, 2017: Agilent Technologies Introduces New GC/Q-TOF System Enabling Greater Exploration of Unknown Chemical Samples 73
Jun 06, 2016: Agilent Technologies Launches New Solutions for Pharma, Biopharma, Metabolomics and Environmental Researchers Across Mass Spec Portfolio 74
Jun 05, 2017: Agilent Technologies Announces Revolutionary Triple Quadrupole Mass Spectrometer 75
May 10, 2016: Agilent Technologies Introduces InfinityLab Liquid Chromatography Instruments, Columns and Supplies 76
Apr 18, 2016: Agilent Technologies Introduces First Commercial Software for Metabolic Flux Analysis 77
Mar 21, 2017: Agilent Technologies Enhances Exome Sequencing for Clinical Research 78
Mar 08, 2017: Agilent Technologies Launches New Research-Grade Triple Quadrupole LC/MS System 79
Mar 07, 2017: Agilent Technologies Extends Biopharma Portfolio with Advanced Mass Spec System 80
Other Significant Developments 81
Oct 17, 2017: Agilent Expands SureGuide Portfolio with CRISPR-based Products to Accelerate Disease Research 81
Oct 20, 2016: Agilent Technologies Launches SureGuide CRISPR Libraries for Functional Genomics 82
Feb 11, 2016: Agilent Technologies Announces Early Access to Custom guideRNA for Functional Genomics 83
Feb 11, 2016: TRADE NEWS: Agilent Technologies Announces Early Access to Custom guideRNA for Functional Genomics 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
Agilent Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Agilent Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Agilent Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Agilent Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Agilent Technologies Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Agilent Technologies Inc, Medical Devices Deals, 2011 to YTD 2017 11
Agilent Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Agilent Technologies Acquires Product Line Of Aurora SFC Systems 15
Molecular Assemblies Raises USD2.3 Million in Seed Financing 16
Agilent Tech Extends its Agreement with University of Leuven - Center for Human Genetics and University Hospitals Leuven 17
Agilent Technologies Enters into Agreement with Transcriptic 18
Agilent Technologies Enters into Distributuion Agreement with PureHoney Technologies 19
Protea Biosciences Enters into Agreement with Agilent Technologies 20
Agilent Technologies Enters into Agreement with Bioprocessing Technology Institute 21
Dako Enters into Development Agreement with ONO PHARMA for Opdivo 22
Agilent Technologies And CambTEK Enter Into Co-Marketing Agreement For Sample Prep Technologies 23
Agilent Technologies Enters Into Agreement With Cell Line Genetics For Regenerative Medicine 24
Agilent Technologies Enters Into Co-Marketing Agreement Picometrics 25
Dako Enters Into Co-Development Agreement With Merck 26
Agilent Technologies Enters Into Research Agreement With University of Queensland 27
ModiQuest Research Extends Agreement With Dako To Generate Monoclonal Antibody 28
Agilent Enters Into Research Agreement With Daegu Gyeongbuk Institute of Science And Technology 29
Agilent Technologies Enters Into Co-Development Agreement With Seoul National University Hospital 30
Agilent Technologies Enters Into Agreement With SomaLogic For SOMAscan Proteomic Assay 31
Agilent Technologies Enters Into Agreement With University of Rouen And Bioprocessing Technology Institute For Biologics And Vaccine Analysis 32
Agilent Enters Into Research Agreement With Chungnam National University 33
Agilent Technologies Enters Into Agreement With Applied Proteomics 34
Agilent Technologies Enters Into Research Agreement With Centre for Omic Sciences For Systems Biology 35
Agilent Technologies Enters Into Technology Integration Agreement With Premier Biosoft International 36
Agilent Technologies Enters Into Co-Development Agreement With Beijing Genomics Institute 37
Dako Enters Into Co-Development Agreement With Amgen 38
Dako Enters Into Co-Development Agreement With Amgen 39
Dako Enters Into Co-Development Agreement With Bristol-Myers 40
Agilent Technologies And University of Technology Sydney Expand Their Joint Venture 41
Agilent Technologies Enters Into Co-Development Agreement With Chungnam National University 42
Agilent Technologies Enters Into Research And Development Agreement With National University Of Singapore 43
Dako Denmark Enters Into Co-Development Agreement With Epitomics 44
Agilent Technologies Enters Into Co-Marketing Agreement With Sage Science 45
Nikon Instruments Enters Into Distribution Agreement With Agilent Technologies 46
Dako Enters into Licensing Agreement with OriGene Technologies 47
Population Genetics Enters Into Licensing Agreement With Agilent Technologies For VeriTag Technology 48
Agilent Technologies Completes Public Offering Of Notes Due 2022 For US$400 Million 49
Agilent Technologies Acquires 48% Stake in Lasergen for USD80 Million 51
Agilent Technologies Acquires Cartagenia for USD68.34 Million 52
Agilent Technologies To Acquire ABC Instrumentacion Analitica 53
Agilent Technologies Acquires Minority Stake In Gen9 For US$21 Million 54
Agilent Technologies Completes Acquisition Of Dako From EQT For US$2.2 Billion 55
Agilent Technologies Completes Acquisition Of BioSystem Development 57
Agilent Technologies Acquires Halo Genomics 58
Agilent Technologies Acquires BIOCIUS Life Sciences 59
Agilent Technologies Inc, Key Competitors 60
Agilent Technologies Inc, Key Employees 61
Agilent Technologies Inc, Subsidiaries 63

★海外企業調査レポート[Agilent Technologies Inc (A)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Lannett Co Inc (LCI)：企業の財務・戦略的SWOT分析
    Lannett Co Inc (LCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mazars：企業の戦略的SWOT分析
    Mazars - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Macquarie Telecom Group Limited (MAQ)：企業の財務・戦略的SWOT分析
    Macquarie Telecom Group Limited (MAQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • SKY Network Television Limited (SKT)：企業の財務・戦略的SWOT分析
    SKY Network Television Limited (SKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Methanol Chemicals Co (2001)：企業の財務・戦略的SWOT分析
    Methanol Chemicals Co (2001) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • European Bank for Reconstruction and Development：企業のM&A・事業提携・投資動向
    European Bank for Reconstruction and Development - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's European Bank for Reconstruction and Development Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descri …
  • permanent tsb Group Holdings p.l.c.：企業の戦略・SWOT・財務情報
    permanent tsb Group Holdings p.l.c. - Strategy, SWOT and Corporate Finance Report Summary permanent tsb Group Holdings p.l.c. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Cabot Oil & Gas Corp (COG)：企業の財務・戦略的SWOT分析
    Cabot Oil & Gas Corp (COG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Provogue (India) Limited (PROVOGE)：企業の財務・戦略的SWOT分析
    Provogue (India) Limited (PROVOGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Dottikon ES Holding AG (DESN)：企業の財務・戦略的SWOT分析
    Dottikon ES Holding AG (DESN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Wilmar International Limited：企業の戦略・SWOT・財務分析
    Wilmar International Limited - Strategy, SWOT and Corporate Finance Report Summary Wilmar International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Mulberry Group PLC (MUL)：企業の財務・戦略的SWOT分析
    Mulberry Group PLC (MUL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • J.B. Hunt Transport Services, Inc. (JBHT)：企業の財務・戦略的SWOT分析
    J.B. Hunt Transport Services, Inc. (JBHT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • gel-e Inc：製品パイプライン分析
    Summary gel-e Inc (gel-e), formerly Remedium Technologies Inc is a medical device company that offers products for the treatment of acute wounds. The company's products include spray foams, bandages, gels, films, and band-aids. It offers proprietary technology platform that helps in development of w …
  • Steel Authority Of India Ltd：企業の戦略・SWOT・財務分析
    Steel Authority Of India Ltd - Strategy, SWOT and Corporate Finance Report Summary Steel Authority Of India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Australian Postal Corporation：戦略・SWOT・企業財務分析
    Australian Postal Corporation - Strategy, SWOT and Corporate Finance Report Summary Australian Postal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Brighthouse Financial, Inc. (BHF)：企業の財務・戦略的SWOT分析
    Brighthouse Financial, Inc. (BHF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • AntriaBio Inc (ANTB)-製薬・医療分野：企業M&A・提携分析
    Summary AntriaBio Inc (AntriaBio), formerly AntriaBio Delaware Inc is a biopharmaceutical company that develops drug therapies for the treatment of diabetes and metabolic diseases. The company’s lead product candidate include AB10, human recombinant insulin for use in type 1 and type 2 diabetes for …
  • VWR Corp：医療機器：M&Aディール及び事業提携情報
    Summary VWR Corp (VWR), a subsidiary of Avantor Performance Materials Inc, is a medical equipment company that distributes laboratory products, and provides services and solutions. The company offers product such chemicals, reagents, consumables, durable products, scientific equipment and instrument …
  • Castrol India Ltd (CASTROLIND)：企業の財務・戦略的SWOT分析
    Summary Castrol India Ltd (Castrol India), a subsidiary of Castrol Limited, is an oil and gas company that manufactures, distributes and markets lubricant products. The company provides products such as lubricants, premium lubricating oils and greases, antifreeze and coolant, greases, engine oils, d …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆